Recently, Yuze Biotechnology Co., Ltd. (hereinafter referred to as “Yuze Bioâ€), a tumor-accurate immune diagnosis and treatment company incubated by VÏ€ Zhangjiang incubator, completed several hundred million rounds of financing. This round of financing, led by IDG Capital, will be used to expand clinical and pharmaceutical cooperation, and to promote neoantigen detection and verification services, providing "off the shelf" high-quality nascent antigen targets for individualized immunotherapy.
Established in 2015, Yuce Bio is a high-tech enterprise specializing in the detection of tumor immunotherapy. With the combination of “gene†and “immunityâ€, it combines tumor genome and immune microenvironment to help tumor patients choose the most suitable one. Treatment programs. include:
Find biomarkers related to the efficacy of immunotherapy, provide tumor genomics solutions, assist doctors in making correct clinical decisions, and work with companies to develop credible immunotherapy efficacy monitoring techniques, such as predicting the sensitivity of PD-1 medications , drug resistance, false progress, super progress, etc.;
Cooperate with downstream cell therapy institutions to develop new tumor immunotherapy based on nascent antigens, such as personalized vaccine based on nascent antigen, TCR-T treatment, CAR-T therapeutic target development, TILs treatment, etc., to provide personalized tumor vaccine for cancer patients. And precise adoptive cell therapy programs.
At present, Yuce Bio has launched the comprehensive genetic testing product YuceOne Plus, which is used to guide tumor immunotherapy, targeted therapy and chemotherapy, and the genetic testing product YuceOne ICIs based on multiple indicators to evaluate the efficacy of immunological checkpoint inhibitors.
Yuce Bio has been awarded the National High-tech Enterprise Certification and Shenzhen High-tech Enterprise Certification, and has become the first Chinese company to join the International Newborn Antigen Screening Alliance. Its testing business has covered more than 200 hospitals nationwide, and together with more than 10 domestic institutions to develop tumor immunotherapy based on nascent antigen.
On March 1, 2017, the China Anti-Cancer and Ladder Program jointly launched by Yu Ce Biological and Dr. Zhan Qimin was the first genomic cooperation program in China for tumor immunotherapy. Based on China's rich clinical resources for tumor immunotherapy, the program aims to promote clinical data based on deep understanding of the interaction between the human immune system and tumor cells, through genomic research and bioinformatics big data analysis, artificial intelligence and other technologies. Development and utilization of specific antigens and biomarkers for tumor immunotherapy. At present, it has been approved by 60+ experts, signed 50+ hospitals, 6+ enterprises, and has accumulated 500+ IO treatment test cases.
Founder & CEO Gao Zhibo said that tumor immunotherapy is a breakthrough in the Nobel Prize, which fundamentally changed the paradigm of the entire tumor diagnosis and treatment. O medicine and K medicine are also listed in China, and the future development is very promising, and the new antigen is connected. The key to "gene" and "immunity".
IDG Capital Partner Yang Fei said: Life and health is the ultimate goal of medical pursuit, and cancer is the number one killer threatening human health. In the past, people talked about cancer discoloration. Traditional treatment methods are difficult to cure tumors, but tumor immunotherapy has brought us this possibility. Whether it is anti-PD-1 drugs or CAR-T treatments, it carries "cure cancer." "The hope."
Pu Yang Medical Management Partner Zhou Mi and Director Li Yang said that precision medicine and tumors are "twin brothers". Genetic testing plays a fundamental role in the precise treatment of tumors. Tumor immunodiagnosis is in the ascendant and has received widespread attention since last year. A lot of breakthroughs. Tumor immunodiagnosis requires consideration of both genetic and immunological factors. Yuce Bio is synchronizing with leading international companies in key nascent antigen detection technologies.
Wang Xuegang, founder of Shell Society, said that the ladder project initiated by Yuce Bio is the first real-world study on tumor immunotherapy in China. It is expected that the ladder 3D (gene, immune, clinical) database will bring more suitable products to China. Diagnostic markers and therapeutic targets for the population.
Guo Qiushan, managing partner of Miracle Light Fund, said that in the past year, the product line of tumor immunotherapy surged by 67%, and the research and development pipeline and cell therapy project targeting tumor neonatal antigens achieved triple-digit growth. Yuce Bio has always stood in technology. The forefront of research and development.
Small Cable Reel,Self Retracting Cable Reel,Auto Rewind Water Hose Reel,Wall Mount Water Hose Reel
NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.cxhosereel.com